SCHEMBL11900387

SCHEMBL11900387

COc1cnc(SC)[nH]c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ POLB P06746 3/20 0.54
▸ KDM6B O15054 1/20 0.53
▸ KDM4A O75164 1/20 0.53
▸ KDM4D Q6B0I6 1/20 0.53
▸ HIF1AN Q9NWT6 1/20 0.53
▸ KDM2A Q9Y2K7 1/20 0.53
▸ RECQL P46063 1/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ HTT P42858 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GRIN2D O15399 1/20 0.38
▸ GRIN3B O60391 1/20 0.38
▸ GRIN1 Q05586 1/20 0.38
▸ GRIN2A Q12879 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11450223 0.75 LMNA (0.52) LMNAALDH1A1KDM6BKDM4AKDM4D
SCHEMBL7708436 0.75 LMNA (0.52) LMNAPOLBKDM6BKDM4AKDM4D
SCHEMBL10733172 0.75 LMNA (1.00) LMNAALDH1A1POLBKDM6BKDM4A
SCHEMBL26669557 0.75 RECQL (0.54) LMNAKDM4EALDH1A1POLBRECQL
SCHEMBL3577936 0.75 KDM6B (0.58) LMNAKDM4EALDH1A1POLBKDM6B
SCHEMBL10731119 0.74 DHFR (0.49) LMNAALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL10618505 0.74 LMNA (0.51) LMNAKDM4EALDH1A1POLBKDM6B
SCHEMBL2433371 0.73 RECQL (0.53) LMNAKDM4EALDH1A1POLBRECQL
SCHEMBL13525026 0.73 KDM6B (0.61) LMNAKDM6BKDM4AKDM4DHIF1AN
SCHEMBL2713726 0.73 KDM6B (0.56) LMNAALDH1A1POLBKDM6BKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473486-B1 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2015-10-28 — — EP disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 — — US disclosed
WO-2011026835-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists HAMP, DHPS, SLC40A1 LMNA 4333/4885KDM4E 3527/4885ALDH1A1 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback